Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Enavogliflozin reduces leptin in type 2 diabetes
Last updated September 3, 2026
Key finding
LS mean difference of -2.99 µg/L.
The phase III trial investigated the effects of Enavogliflozin on leptin levels in type 2 diabetes patients, finding a significant decrease in leptin levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The phase III trial investigated the effects of Enavogliflozin on leptin levels in type 2 diabetes patients, finding a significant decrease in leptin levels.
Clinical relevance
The findings suggest that Enavogliflozin may be an effective treatment option for managing type 2 diabetes by not only improving glycemic control but also reducing leptin levels, which are associated with obesity and insulin resistance. This could lead to better overall health outcomes for patients with diabetes.
Keep in mind
The study did not include long-term follow-up data. Sample size and demographic diversity may limit generalizability. Adiponectin changes were not significant, indicating mixed results.
Published in
Journal Reference
Publication details and source links for this paper.
Young SL, Hansol L, Kyung-Soo K, Sangmo H, Cheol-Young P. Enavogliflozin treatment decreased leptin levels in patients with type 2 diabetes: a phase III trial. Cardiovascular Diabetology. 2025;24:355. doi:10.1186/s12933-025-02917-z
Main Effects
Leptin levels decreased significantly with an LS mean difference of -2.99 µg/L (p < 0.0001).
HbA1c decreased with an LS mean difference of -0.99% (p < 0.0001).
Fasting Plasma Glucose decreased with an LS mean difference of -40.08 mg/dL (p < 0.0001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Enavogliflozin 0.3 mg and Adiponectin, BMI, Body weight, and 7 more.
This study contributes evidence to
Primary intervention
Enavogliflozin 0.3 mg
Primary outcomes
- Adiponectin
- BMI
- Body weight
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
10
Evidence pairs
1659
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Blood Pressure
matched_outcome
Related evidence
Evidence topic
Weight Loss
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiastolic blood pressure
Enavogliflozin 0.3 mg → Diastolic blood pressure
Enavogliflozin 0.3 mg → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Enavogliflozin 0.3 mg → Fasting Plasma Glucose (FPG)
Enavogliflozin 0.3 mg → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Enavogliflozin 0.3 mg → Insulin resistance
Enavogliflozin 0.3 mg → Insulin resistance
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean leptin level change
Enavogliflozin 0.3 mg → Mean leptin level change
Enavogliflozin 0.3 mg → Mean leptin level change
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSystolic blood pressure
Enavogliflozin 0.3 mg → Systolic blood pressure
Enavogliflozin 0.3 mg → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Leptin levels decreased significantly by -2.99 µg/L.
- HbA1c levels improved by -0.99%, indicating better blood sugar control.
- Fasting Plasma Glucose levels dropped by -40.08 mg/dL.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients seeking additional treatment options for diabetes management.
Keep in Mind
- Results may not apply to populations outside the study demographics.
- Further research is needed to confirm long-term effects.
- The study's findings are based on a specific dosage of Enavogliflozin.
Between the Lines
- The study did not include long-term follow-up data.
- Sample size and demographic diversity may limit generalizability.
- Adiponectin changes were not significant, indicating mixed results.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Enavogliflozin 0.3 mg and Adipokine and Angiogenic Markers, Enavogliflozin 0.3 mg and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Enavogliflozin 0.3 mg → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Enavogliflozin 0.3 mg → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
1 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Enavogliflozin 0.3 mg Evidence Hub
All studies on Enavogliflozin 0.3 mg
1 studies
intervention_hubContributes to Enavogliflozin 0.3 mg evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Enavogliflozin 0.3 mg and Adiponectin
Intervention: Enavogliflozin 0.3 mgOutcome: Adiponectin
1 results
All studies on Enavogliflozin 0.3 mg and BMI
Intervention: Enavogliflozin 0.3 mgOutcome: BMI
1 results
All studies on Enavogliflozin 0.3 mg
Intervention: Enavogliflozin 0.3 mg
1 results
All studies measuring Adiponectin
Outcome: Adiponectin
1 results
All studies measuring BMI
Outcome: BMI
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Enavogliflozin 0.3 mg affect BMI?
Emerging Evidence
Enavogliflozin 0.3 mg appears to affect BMI.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Enavogliflozin 0.3 mg affect body weight?
Emerging Evidence
Enavogliflozin 0.3 mg appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Enavogliflozin 0.3 mg improve diastolic blood pressure?
Emerging Evidence
Enavogliflozin 0.3 mg appears to improve diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Enavogliflozin 0.3 mg improve fasting plasma glucose (FPG)?
Emerging Evidence
Enavogliflozin 0.3 mg appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Phone-delivered diabetes education improves self-care behaviorsBariatric surgery improves glucose homeostasis in type 2 diabetes.Combination therapy improves liver health in type 2 diabetesExercise Improves Serum Albumin Levels in Women with Type 2 DiabetesInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.